Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

Video

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, University of Southern California, Norris Comprehensive Cancer Center and Hospital, discusses the role of PD-L1 testing for immune checkpoint inhibitor therapy in lung cancer.

In second-line lung cancer therapy, where all the data is currently, it appears that PD-L1 by immunohistochemistry staining is not the best marker, says Gitlitz.

It can enrich for some patients that are more likely to respond, but it is hard to pick the people who should not get these drugs. This is because patients with low levels or no levels of PD-L1 are having a response.

At this time, PD-L1 is not a good enough marker to exclude patients from receiving immunotherapy, says Gitlitz.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD